Safety
As shown in the Table 3, the incidence of any grade treatment-related
AEs was 73.07% (57/78), including 7 cases of grade 4 adverse reactions,
3 cases of myelosuppression, 2 cases of pneumonia, 1 case of superior
vena cava occlusion, and 1 case of ketoacidosis. No fatal effects
happened. Among the treatment-related AEs, the incidence of leukopenia
was the highest (57.69%), followed by anemia (25.64%), elevated
alanine aminotransferase or aspartate aminotransferase (24.36%) and
fatigue (24.59%).